Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?

BACKGROUND AND OBJECTIVES: Patients with multiple sclerosis (PwMS) receiving extended dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that maintenance of deep depletion of circulating B cells is not necessary to maintain the efficacy of RTX in MS. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Claverie, Roxane, Perriguey, Marine, Rico, Audrey, Boutiere, Clemence, Demortiere, Sarah, Durozard, Pierre, Hilezian, Frederic, Dubrou, Clea, Vely, Frederic, Pelletier, Jean, Audoin, Bertrand, Maarouf, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442066/
https://www.ncbi.nlm.nih.gov/pubmed/37604695
http://dx.doi.org/10.1212/NXI.0000000000200152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442066/
https://www.ncbi.nlm.nih.gov/pubmed/37604695
http://dx.doi.org/10.1212/NXI.0000000000200152

Ejemplares similares